糖尿病并非连续流左心室辅助装置支持患者的死亡危险因素
该系统评价与荟萃分析纳入4项研究共1120例连续流左心室辅助装置(CF-LVAD)患者,其中糖尿病478例、非糖尿病642例。
要点
- 感染、短暂性脑缺血发作、颅内出血及泵血栓风险在糖尿病与非糖尿病组间无显著差异。
- 当代CF-LVAD支持下,术前糖尿病不应作为排除或延迟支持的独立依据。
核心结论
- 糖尿病不增加当代连续流左心室辅助装置(CF-LVAD)支持患者的全因死亡率及主要不良事件发生率。
研究设计与样本
- 系统检索PubMed、Embase、ISI Web of Knowledge及Cochrane Central Register of Controlled Trials后行荟萃分析。
- 共纳入4项研究、1120例患者,其中糖尿病478例、非糖尿病642例。
- 主要终点为全因死亡风险比(HR),次要终点为术后并发症的合并比值比(OR)。
临床怎么用
- 在评估CF-LVAD候选者时,不应仅因合并糖尿病而排除或延迟机械循环支持。
- 对糖尿病CF-LVAD患者仍需常规监测感染、神经系统事件及泵血栓等并发症。
局限性
- 纳入研究仅4项、总样本1120例,证据基础有限。
- 荟萃分析基于观察性研究,可能存在混杂偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus has been proved to be a potent, independent risk factor for mortality in patients with heart failure. However, the influence of diabetes on outcomes after continuous-flow left ventricular assist device (CF-LVAD) implantation is still under debate. This study sought to investigate the effect of preoperative diabetes on all-cause mortality and major postoperative complications among patients with contemporary CF-LVAD support. METHODS: A systematic literature search (PubMed, Embase, and ISI Web of Knowledge, and Cochrane Central Register of Controlled Trials) was performed. The primary endpoint was hazard ratio for all-cause mortality. Secondary endpoints were postoperative complications, including infection, transient ischemia attack, intracranial hemorrhage, and pump thrombosis. A meta-analysis was conducted to generate pooled hazard ratio and 95% confidence interval (CI) for all-cause mortality and pooled odds ratio (OR) and 95% CI for postoperative complications. RESULTS: A total of 1120 patients (478 diabetic patients, 642 nondiabetic patients) from four studies were included in this study. Diabetes did not increase the risk for all-cause mortality among patients with CF-LVAD support (hazard ratio 1.33; 95% CI, 0.88 to 2.02; P = .18). Moreover, pooled analysis demonstrated no significant difference was found in the diabetes and nondiabetes groups in terms of infection (OR 1.18; 95% CI, 0.89 to 1.56; P = .24), transient ischemia attack (OR 1.30; 95% CI, 0.86 to 1.97; P = .21), intracranial hemorrhage (OR 1.86; 95% CI, 0.93 to 3.71; P = .08), and pump thrombosis (OR 1.01; 95% CI, 0.68 to 1.48; P = .97). CONCLUSIONS: The results of this meta-analysis demonstrate that diabetes does not increase all-cause mortality or rates of major adverse events during contemporary CF-LVAD support.
引用
- Zhou P, Xiao Z, Zhu P, et al. Diabetes Mellitus Is Not a Risk Factor for Patients Supported With Left Ventricular Assist Device. Ann Thorac Surg. 2019. PMID: 31610168. doi:10.1016/j.athoracsur.2019.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。